Literature DB >> 24239146

Urinary neutrophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis.

Wei Zhu1, Min Liu1, Guang-Chun Wang1, Jian-Ping Che1, Yun-Fei Xu1, Bo Peng1, Jun-Hua Zheng2.   

Abstract

BACKGROUND: The objective of this study was to determine the diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL), C-reactive protein (CRP), and procalcitonin (PCT) in the prognosis of patients presenting with the systemic inflammatory response syndrome (SIRS) with nephrolithiasis.
METHODS: Urine NGAL protein levels were measured by enzyme-linked immunosorbent assay in 87 patients presenting with nephrolithiasis who were diagnosed as SIRS. Additionally, 52 patients presenting with nephrolithiasis but without urinary tract infection and 30 healthy controls were also included in the study. Levels of serum CRP and PCT were also taken into consideration.
RESULTS: Median urinary NGAL levels were significantly increased in the SIRS cohorts compared with nephrolithiasis without urinary tract infection patients (4.28 ng/mL versus 2.69 ng/mL, P < 0.001), and NGAL was markedly elevated even in the early stage of SIRS (3.23 ng/mL versus 2.69 ng/mL, P < 0.001). According to the receiver-operating characteristic analysis, NGAL demonstrated a high diagnostic value compared with either PCT or CRP. In the later stage of SIRS, NGAL remained a highly sensitive (76.8%) and specific (86.5%) diagnostic marker compared with either PCT or CRP. Moreover, the area under the curves of NGAL (0.822) were also superior to those seen in either PCT (0.657) or CRP (0.761).
CONCLUSION: Urinary NGAL is a highly sensitive and specific predictor of SIRS for patients presenting with nephrolithiasis. Further study of NGAL as a reliable biomarker of SIRS is required.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ELISA; NGAL; Nephrolithiasis; SIRS

Mesh:

Substances:

Year:  2013        PMID: 24239146     DOI: 10.1016/j.jss.2013.09.036

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Urinary biomarkers in the early detection and follow-up of tubular injury in childhood urolithiasis.

Authors:  Mehmet Taşdemir; Dilara Fuçucuoğlu; Suat Hayri Küçük; Meltem Erol; Özgül Yiğit; Ilmay Bilge
Journal:  Clin Exp Nephrol       Date:  2017-06-26       Impact factor: 2.801

2.  One-Shot Full-Range Quantification of Multi-Biomarkers With Different Abundance by a Tandem Giant Magnetoresistance Assay.

Authors:  Fanda Meng; Lei Zhang; Jie Lian; Weisong Huo; Xizeng Shi; Yunhua Gao
Journal:  Front Chem       Date:  2022-05-19       Impact factor: 5.545

3.  Clinical significance of neutrophil gelatinase-associated lipocalin in Crimean-Congo hemorrhagic Fever.

Authors:  Ayse Erturk; Erkan Cure; Emine Parlak; Medine Cumhur Cure; Serap Baydur Sahin; Suleyman Yuce
Journal:  Biomed Res Int       Date:  2015-01-22       Impact factor: 3.411

4.  Systemic inflammatory response syndrome in patients with acute obstructive upper tract urinary stone: a risk factor for urgent renal drainage and revisit to the emergency department.

Authors:  Spencer Larkin; Jeremy Johnson; Trisha Venkatesh; Joel Vetter; Ramakrishna Venkatesh
Journal:  BMC Urol       Date:  2020-06-29       Impact factor: 2.264

5.  Effects of short-term atorvastatin use in patients with calcium stones: A randomized placebo-controlled clinical trial.

Authors:  Fatemeh Taheri; Maryam Taheri; Abbas Basiri; Alireza Khoshdel; Fariba Samadian; Sanaz Tavasoli
Journal:  Investig Clin Urol       Date:  2019-10-22

6.  Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria.

Authors:  Xiangling Wang; Gauri Bhutani; Lisa E Vaughan; Felicity T Enders; Zejfa Haskic; Dawn Milliner; John C Lieske
Journal:  BMC Nephrol       Date:  2020-04-15       Impact factor: 2.388

7.  The role of specific biomarkers, as predictors of post-operative complications following flexible ureterorenoscopy (FURS), for the treatment of kidney stones: a single-centre observational clinical pilot-study in 37 patients.

Authors:  Stephen Fôn Hughes; Alyson Jayne Moyes; Rebecca May Lamb; Peter Ella-Tongwiis; Christopher Bell; Ahmed Moussa; Iqbal Shergill
Journal:  BMC Urol       Date:  2020-08-14       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.